We’re a close-knit team, dedicated to providing outstanding service to clients, candidates and stakeholders. Our experience and industry knowledge are well regarded in the life science sector, where we have established a reputation for clarity and sound advice. PiR is a positive, informed and supportive environment for clients, candidates and staff, and a place where good ideas grow.
Carolyn founded PiR in response to the industry’s need for flexible, knowledgeable and trusted recruitment services for early stage and mid-capped life science companies. Under Carolyn’s leadership, PiR has developed an impressive network of Executive and Non-Executive leaders with medical, commercial and financial expertise. She has built a company that truly understands the role that outstanding talent plays in supporting early stage businesses as they develop and monetise their products and services. In November 2016 Carolyn became Non-Executive Chair as part of the company’s succession planning.
Sally is known for bringing fresh ideas, energy and drive to business and excels at understanding client and candidate expectations. Under Sally’s leadership, PiR has grown from the new relationships she has fostered with her team. Sally’s collaborative and pragmatic leadership style encourages individualism and team based success, ensuring the best solutions and outcomes for clients and candidates alike. With encouragement from Sally, PiR has broadened its services to include Interim Management, Executive Search and Talent Mapping across all life science functions and geographies.
Jayne has returned to PiR as Project Director, right hand to the CEO and a key member of the senior management team. Her significant commercial and project management experience, gained in a variety of different sectors, will be invaluable to the PiR business. Her focus on delivering solutions and quality service aligns with PiR’s ethos when supporting clients and candidates in executive search and interim projects. In addition, Jayne will manage corporate events and work with the Board on the on-going growth of the company. Her interest in people is vital for a people focused business and evident from the rapport she builds with all she meets. Jayne brings a great work ethic, insight, and focus on results in a fast-moving culture. She is able to encourage colleagues to go that extra mile, always with a smile, and is a pragmatic voice of reason.
Paul has been with PiR since 2012 and as Senior Executive Researcher, works on executive search projects for our clients. He is renowned for his calm and tenacious approach, leaving nothing to chance and delivering outstanding shortlists for client projects. Clients, candidates and colleagues value his deep understanding of the life science sector and his ability to forge strong relationships. Paul has supported clients in start-ups, SMEs and multi-national pharmaceutical, biotechnology, diagnostic and medical device organisations. He graduated from the University of Northampton with a first class BA (Hons) Degree in Business Management.
Emma joined PiR in 2018, strengthening the Interim Management team as demand from clients grows. Building strong relationships with highly qualified, first class professionals, allowing her to gain valuable market insight and intelligence, is paramount in her role. Thriving on the ability to build rapport quickly, she enjoys widening her network and building continuous industry knowledge. Emma works meticulously when managing interim client projects; for early stage investor backed start-ups, SMEs and multinationals in pharmaceutical, biotechnology, diagnostic and medical device organisations. Clients value her concise, informative candidate summaries, demonstrating her clear understanding of business need, whilst ensuring discussion with candidates is meaningful and appropriate. Emma’s experience of working in the acute health sector, for the past 6 years, equips her with many skills that are invaluable to the Life Science industry; medical and industry knowledge, ability to be flexible, an energetic and lively pace, engaging with a range of stakeholders who appreciate her calm and cheerful demeanour.
Sarah joined PiR in 2018 as Executive Interims Consultant to build on the success of PiR’s interims business. Her focus is to create sustainable relationships with both clients and interim professionals; using her natural rapport building skills and industry insight. Sarah brings to PiR significant experience of working within the recruitment industry, delivering hiring solutions for commercial roles with start-ups, SMEs and corporate clients. She thrives on learning about the different facets of the life science industry. Through insightful questioning, she builds an understanding of a client brief or a candidate profile; recognising that culture fit is as important as technical or scientific skills and leadership capability. Her candour and interest in soft skills are appreciated by clients and candidates alike. Working closely with the executive search team at PiR, Sarah encourages a collaborative approach which often creates the best outcome for a client project or candidate.
Maureen has amassed over 30 years’ experience within the life science sector, mainly with GlaxoSmithKline finishing as VP Global Strategy Development for GSK. Since 2007 she has been working with a number of investor-backed companies including as founding Chief Executive of NovaThera, a regenerative medicine spin-out from Imperial College London, and as Non-Executive Director and Chairman of life science spin-out companies from Oxford, Kings College Universities and other life science entrepreneurs.
She is a founding Director of MedInnovate Ltd, a technology consultancy spanning the healthcare industry. She is currently Chairman of Parafricta Ltd, a wound care specialist materials company, and CN Bio Innovations – the human organ-on-a-chip technology company whose LiverChip® and Quantum B® human liver models are being well received as a disruptive route to liver modelling for Hepatitis B and NASH drug discovery, and ADME tox testing. She was a founding industry consulting partner at Kinapse Ltd.
Maureen brings a wealth of sector relevant knowledge and contacts and experienced leadership in developing early stage life science businesses and Big Pharma.
Mark obtained his PhD in pharmacology from Cambridge University and then developed novel 3D tissue culture models, as an academic at the University of Basel until 1992. He has over 25 years’ experience in the discovery of novel treatments for diseases with unmet medical need.
Mark formerly worked at Pfizer where he was responsible for research into neurodegenerative diseases. In 1997, Mark set up Cambridge Drug Discovery as Chief Executive, which was then sold to BioFocus (now part of Charles River) in 2001. Since then, Mark has worked with many early-stage biotechnology companies from foundation through to trade sale or transition onto the public markets. More recently, he was Chief Executive of the Life Sciences Organisation of UK Trade & Investment, which helped UK-based Life Sciences companies raise investment and export overseas. Mark is currently Chief Executive of Cellesce as well as Chairman of NuVision Biotherapies, Ubiquigent and Talisman Therapeutics.
Mark has a background in early stage medtech companies, supporting them from start up to successful exit via trade sale and flotation. Most recently he has held various roles as Chairman or CEO of high potential medtech start-ups and he chairs a panel of the NIHR i4i translational funding scheme for the advancement of healthcare technologies for NHS patients. He began his career as a chartered mechanical engineer before joining the medical device start-up, Medic-Aid Ltd, where, as CEO, he led the company to a management buyout and subsequently listing on the Main Market of the London Stock Exchange before completing a trade sale to Respironics Inc. Since selling his business he has chaired several medtech start-ups and he successfully sold Nigaard Pharma A/S to Zambon Spa in 2015.
Chris is well known amongst the early stage investor and board communities, particularly for his work with Oxford Spinout Equity Management (OSEM), where he invested £12m in university spinouts, returning £40m to the university and growing the overall value of the equity portfolio. Prior to this he held senior roles at Glaxo and GlaxoWellcome for over 23 years, including leadership of the development teams behind major novel therapies (including Imigran, Zofran and Relenza). He also served as a member of the Corporate Strategy Team in a period of significant organisational change. In 2001, he joined Imperial College London to assist the new Vice Chancellor, Sir Richard Sykes, in a variety of ways including strategic planning, complex project management, the commercialisation of science and leadership of the Communications Team. He has a PhD in Biochemistry and post-doctoral research experience in the use of oncofoetal antigens as markers of cancer presence or abnormal placental function.